Boston Scientific Buyouts Grow R&D, Offer Liquid Exit For Device Start-Ups
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's strategy to engage emerging medical device companies in a variety of collaborative arrangements provides the company an important source of R&D as well as an attractive exit strategy for the device start-ups, according to Frank Grillo, director of new business development.